Stereotactic Body Radiotherapy Feasible After Radical Prostatectomy
By Elana Gotkine HealthDay Reporter
TUESDAY, May 20, 2025 -- Post-radical prostatectomy (post-RP) stereotactic body radiotherapy (SBRT) is well tolerated, with patient-reported outcomes (PROs) comparable to those seen after postoperative conventionally fractionated radiotherapy (CFRT) for prostate cancer, according to a study published online May 15 in JAMA Oncology.
John Nikitas, M.D., from the University of California, Los Angeles, and colleagues examined physician-reported late toxic effects and two-year PROs following post-RP SBRT in a phase 2, single-arm trial. One hundred men with post-RP prostate-specific antigen greater than 0.03 ng/mL or adverse pathologic features were treated with post-RP SBRT and followed for a median of 43 months. The longitudinal PROs for men receiving SBRT were compared to those of 200 men receiving postoperative CFRT.
The researchers found that the cumulative incidence of late grade 2 and 3 genitourinary toxic effects and gastrointestinal tract toxic effects was 25 and 4 percent and 3 and 3 percent, respectively. Overall, 38.9, 17.9, and 34.1 percent of patients had decrements of more than twofold the minimal clinically important difference (MCID) in PROs for urinary incontinence, urinary irritation, and bowel function, respectively. The adjusted odds ratios for patients receiving SBRT experiencing decrements more than twofold the MCID were not significant when compared with the CFRT cohort for urinary incontinence, urinary irritation, and bowel function.
"There was no measurably different decline in urinary, bowel, or sexual function through two years compared with a cohort of patients treated using CFRT," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Use of Composite Allocation Score for Lung Transplant Wait List Improves Outcomes
MONDAY, May 19, 2025 -- Wait-list outcomes for lung transplants have substantially improved in the composite allocation score (CAS) era, according to a study presented at the...
MRI-Guided Biopsy Linked to Durability of Active Surveillance in Prostate Cancer
MONDAY, May 19, 2025 -- Use of magnetic resonance imaging (MRI)-guided biopsy (MRGB) could increase the durability of active surveillance (AS) in men with prostate cancer...
Preinjury Mobility Predicts Adults' Recovery After Lower-Extremity Fracture
THURSDAY, May 15, 2025 -- Preinjury mobility data predicts recovery following a lower-extremity fracture in adults, according to a proof-of-concept study published online April 28...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.